{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:20:14Z","timestamp":1697001614573},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T00:00:00Z","timestamp":1106611200000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:p>Treatment of AIDS\u2010related malignant lymphoma (ARL) remains a therapeutic challenge. There are concerns not only about infectious and haematological complications in HIV\u2010infected patients during intensive chemotherapy, but also about potential interactions between chemotherapy and highly active antiretroviral therapy (HAART). Current data on patients treated concomitantly with intensive chemotherapy and HAART are limited, and no data exist on patients with ARL suffering from active opportunistic infections. We report the case of a 38\u2010year\u2010old man with advanced HIV\u20101 infection, pulmonary tuberculosis and Burkitt's lymphoma. Intensive chemotherapy was administered in parallel with tuberculostatic therapy and HAART. Six months later, the patient achieved not only a complete remission of Burkitt's lymphoma and sustained viral suppression, but also a full recovery from tuberculosis. This case report provides some useful observations on the successful application of intensive chemotherapy in addition to tuberculostatic therapy and HAART in HIV\u2010infected patients.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2005.00262.x","type":"journal-article","created":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T14:02:28Z","timestamp":1106661748000},"page":"51-53","source":"Crossref","is-referenced-by-count":5,"title":["Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS\u2010related Burkitt's lymphoma"],"prefix":"10.1111","volume":"6","author":[{"given":"C","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Wyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,1,25]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200108170-00005"},{"key":"e_1_2_4_3_2","first-page":"4653","article-title":"Highly effective treatment of acquired immunodeficiency syndrome\u2010related lymphoma with dose\u2010adjusted EPOCH","volume":"101","author":"Little RF","year":"2003","journal-title":"impact of antiretroviral therapy suspension and tumor biology"},{"key":"e_1_2_4_4_2","first-page":"1491","article-title":"Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV\u2010associated non\u2010Hodgkin's lymphoma","volume":"22","author":"Sparano JA","year":"2004","journal-title":"an Eastern Cooperative Oncology Group Trial (E1494)"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(97)86004-0"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200012150-00011"},{"key":"e_1_2_4_8_2","first-page":"766","article-title":"Burkitt's lymphoma in adults with and without human immunodeficiency virus infection","volume":"82","author":"Spina M","year":"1998","journal-title":"a single-institution clinicopathologic study of 75 patients"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2339"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2171"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11628"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10365"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241090-00004"},{"key":"e_1_2_4_14_2","doi-asserted-by":"crossref","unstructured":"HoffmannC WolfE FatheuheurGet al.Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS\u2010related lymphoma. AIDS2003;17:1521\u20131529.","DOI":"10.1097\/00002030-200307040-00013"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.00262.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.00262.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:07:48Z","timestamp":1696950468000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.00262.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1111\/j.1468-1293.2005.00262.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00262.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}